ACIXF (Acarix AB) Other Stockholders Equity: $0.32 Mil (As of Mar. 2026)


ACIXF Acarix AB ACIXF
44 GF Score
Price $0.03
GF Value $0.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Acarix AB Other Stockholders Equity?

Acarix AB ACIXF 44 Other Stockholders Equity is $0.32 Mil as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 44/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Acarix AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.32 Mil.

Acarix AB's quarterly Other Stockholders Equity declined from Sep. 2025 ($0.32 Mil) to Dec. 2025 ($0.26 Mil) but then increased from Dec. 2025 ($0.26 Mil) to Mar. 2026 ($0.32 Mil).

Acarix AB's annual Other Stockholders Equity increased from Dec. 2023 ($0.40 Mil) to Dec. 2024 ($0.47 Mil) but then declined from Dec. 2024 ($0.47 Mil) to Dec. 2025 ($0.26 Mil).

Acarix AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Acarix AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB Other Stockholders Equity Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.44 0.40 0.47 0.26

Acarix AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.34 0.32 0.26 0.32
ACIXF
44GF Score
Acarix AB ACIXF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.32 Mil mean?
Acarix AB (ACIXF) has a Other Stockholders Equity of $0.32 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Acarix AB and its competitors.
Is Acarix AB's Other Stockholders Equity too high?
Acarix AB's current Other Stockholders Equity is $0.32 Mil. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Other Stockholders Equity compare to ABT and SYK?
Acarix AB's Other Stockholders Equity of $0.32 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Acarix AB and its competitors. Acarix AB's current Other Stockholders Equity is $0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 44.4% above its estimated fair value. The current Other Stockholders Equity is $0.32 Mil. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Other Stockholders Equity is $0.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of $0.03 is trading 44.4% above its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Significantly Overvalued.

Key valuation signals for ACIXF:

  • Other Stockholders Equity: $0.32 Mil
  • GF Value™: $0.02 vs. price of $0.03 (44.4% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score

Get the complete analysis for ACIXF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price
$0.02
GF Value